目的 探讨2021—2024年中国科学院合肥肿瘤医院口服小分子靶向抗肿瘤药物使用情况和发展趋势，为该类药物的合理应用及规范化管理提供参考依据。方法 以回顾性分析的方法，收集中国科学院合肥肿瘤医院2021年1月1日—2024年12月31日口服小分子靶向抗肿瘤药物的消耗情况信息，逐年分析药物品种数、药品消耗量、年销售金额、销售金额排序、用药频度（DDDs）、DDDs排序、限定日费用（DDC）、药品排序比（B/A）。结果 2021—2024年中国科学院合肥肿瘤医院口服小分子靶向抗肿瘤药物品种为20～23种，年销售金额呈逐年上升的趋势，销售金额居于前3位的品种有安罗替尼、阿帕替尼、阿美替尼、奥希替尼、奥布替尼。2021—2024年总DDDs呈逐年增长的趋势，DDDs排序居于前3位的品种有阿帕替尼、阿美替尼、吉非替尼、安罗替尼、奥希替尼。2021—2024年总DDC呈现逐年下降的趋势，其中销售金额较高的品种中奥希替尼、阿美替尼、阿美替尼的DDC呈现下降趋势，其中奥希替尼连续4年B/A均大于1，同步性良好。结论 中国科学院合肥肿瘤医院2021—2024年口服小分子靶向抗肿瘤药物的使用量和销售金额均呈现逐年增长的趋势，药品价格有下降的趋势，药品使用消耗情况基本符合国家政策要求趋势及本院肿瘤临床治疗的实际需求。

Objective To analyze and discuss the use and development trend of oral small molecule targeted anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences from 2021 to 2024, so as to provide a reference for the rational use and standardized management of such drugs. Methods A retrospective analysis was conducted to collect information on the consumption of oral small molecule targeted anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences from January 1, 2021 to December 31, 2024. The number of drug varieties, drug consumption, annual sales amount, sales amount ranking, frequency of use (DDDs), DDDs ranking, daily cost control (DDC), drug ranking ratio (B/A),and other indicators were analyzed year by year. Results From 2021 to 2024, Hefei Cancer Hospital, Chinese Academy of Sciences has 20 — 23 types of oral small molecule targeted anti-tumor drugs, and the annual sales amount has been increasing year by year. The top three varieties in terms of sales amount are anlotinib, apatinib, amitinib, ositinib, and obetinib. From 2021 to 2024, the total DDDs showed an increasing trend year by year, with apatinib, amitinib, gefitinib, anlotinib, and axitinib ranking among the top three DDDs. From 2021 to 2024, the total DDC showed a decreasing trend year by year, among which the DDC of osimertinib, amitinib, and amitinib with higher sales amounts showed a decreasing trend. Among them, osimertinib had a B/A ratio greater than 1 for four consecutive years, indicating good synchronicity. Conclusion The usage and sales amount of oral small molecule targeted anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences from 2021 to 2024 have shown an increasing trend year by year, with a decreasing trend in drug prices. The consumption of drugs is basically in line with the national policy requirements and the actual needs of Hefei Cancer Hospital, Chinese Academy of Sciences's clinical treatment of tumors.

R979.1